COMPANY PROFILE

HAYA Therapeutics

Explore full profile

A pre-clinical biopharmaceutical company which is developing a first-in-class targeted therapy to treat heart failure

Epalinges, SwitzerlandFounded 2019Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About HAYA Therapeutics

HAYA Therapeutics is an innovative biotechnology company focused on developing next-generation therapies for fibrotic diseases. The company operates in the biopharmaceutical sector, targeting conditions such as heart failure, lung fibrosis, kidney fibrosis, liver fibrosis, and fibrotic processes in solid tumor cancers. HAYA Therapeutics leverages its proprietary discovery engine to identify long non-coding RNAs (lncRNAs) that play a crucial role in tissue and cell-specific fibrosis. Their lead therapeutic candidate is an antisense molecule targeting Wisper, a cardiac-enriched master driver of fibrosis, which has shown promising results in preclinical testing by halting and potentially reversing heart failure-related fibrotic processes. The company's business model revolves around research and development, aiming to bring safe, effective, and accessible anti-fibrotic therapies to market. Revenue generation is expected through the commercialization of these therapies, either independently or through strategic partnerships with larger pharmaceutical companies. HAYA Therapeutics serves patients suffering from fibrotic diseases and collaborates with healthcare providers and research institutions. The company is headquartered at the Biopole Science Park in Lausanne, Switzerland, and is actively expanding its team to support its growth and innovation efforts.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Epalinges, Switzerland
Employees: 69
Open positions: 1
Dealroom signal: 86.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Genetics and genomics, Spinout, Biotech and Pharma, Techbio, Techbio Drug Discovery, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning HAYA Therapeutics.

See all news

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	May 2025	$65M	$260M	Alexandria Venture Investments · Eli Lilly · Apollo Health Ventures · Longview Ventures	↗
SEEDOther financing	Feb 2022	$5M	$20M	Apollo Health Ventures · 4See Ventures · Viva BioInnovator · Humboldt Fund	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

HAYA Therapeutics website traffic

Latest recorded traffic for HAYA Therapeutics is 2.6K monthly website visits, down 39.5% over the last three months. HAYA Therapeutics's team grew 9.5% over the past year.

Latest monthly visits2.6K 3-month web change-39.5% 1-year team growth+9.5%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director I&I Program LeadSan Diego, CA · Human Resources · Sep 2, 2026 Director, Contracts & GovernanceLausanne, Vaud, Switzerland · Other · Sep 1, 2026 Senior Scientist I, Computational Biology (targetID)San Diego, California, United States, Northern America, Americas · Data Science & Engineering · Aug 26, 2026 Research AssociateSan Diego, California, United States, Northern America, Americas · Other · Aug 26, 2026 Director, CMC (Therapeutic Oligonucleotides)San Diego, California, United States, Northern America, Americas · Other · Jul 15, 2026 Senior Scientist II, Data Science (CompBio for Translation and Biomarkers in Cardio-Renal-Metabolics)San Diego, California, United States · Data Science & Engineering · Jan 16, 2026

6 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
GEGenomSysSolutions and Systems for Efficient Genomic Information Processing	Lausanne, Switzerland	Operational	6	$12M	$37M
ABAxol BioscienceSells live human cell cultures and provides services such as genome editing to researchers	Cambridge, United Kingdom	Acquired
BPBC PlatformsA global leader in providing a powerful data and technology platform for personalized medicine and drug development, accelerating the translation of insights into clinical practice	Zurich, Switzerland	Operational
EPEpiternaDeveloping affordable products that can safely slow the ageing process to prevent age-related disease, delay functional decline, and extend life	Epalinges, Switzerland	Operational
DEDefinigenStem cell life science products and services	Babraham, United Kingdom	Operational
INInVirtuoLabsModular AI solutions accelerating drug discovery with predictive models and generative simulations	Lugano, Switzerland	Operational
ABAvenue BiosciencesInnovative protein engineering solutions integrating biologics and machine learning for therapeutic advancements	Palo Alto, United States	Operational
AGAbrinca GenomicsEmpowering researchers and organizations to unlock the secrets of microbial genomics through its user-friendly, scalable platform OpenGenomeBrowser	Bern, Switzerland	Operational